Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial

This publication has 19 references indexed in Scilit:

• Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
  Journal of Clinical Oncology, 2014
• The PCORI Perspective on Patient-Centered Outcomes Research
  JAMA, 2014
• Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial
  Breast Cancer Research and Treatment, 2014
• Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
  The Lancet Oncology, 2014
• A Program of Methodological Research to Arrive at the New International EQ-5D-5L Valuation Protocol
  Value in Health, 2014
• Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper
  Gynecologic Oncology, 2013
• Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
  New England Journal of Medicine, 2012
• Progression-Free Survival: Meaningful or Simply Measurable?
  Journal of Clinical Oncology, 2012
• New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
  European Journal of Cancer, 2009
• Quality-of-Life-Adjusted Evaluation of Adjuvant Therapies for Operable Breast Cancer
  Annals of Internal Medicine, 1991